MedTrace Logo

Enhancement of in-Vitro GC Function in Patients With COPD

NCT00241631 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2019-12-04

Study results available
· View outcomes & findings →

Summary

The investigator wish therefore to continue these studies on theophylline principally by conducting a small clinical pilot study on 20-30 COPD patients in a randomised, double-blind, placebo-controlled, parallel-group study.

Conditions

Interventions

DRUG

Fluticasone Propionate

500 u

DRUG

placebo

DRUG

Theophylline

Theophylline placebo capcule

Sponsors & Collaborators

  • Mitsubishi Tanabe Pharma Corporation

    collaborator INDUSTRY

  • Medical Research Council

    collaborator OTHER_GOV

  • Imperial College London

    lead OTHER

Principal Investigators

  • ian adcock, PhD · Imperial College London

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-04-30
Primary Completion
2007-08-31
Completion
2007-08-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00241631 on ClinicalTrials.gov